Development and Psychometric Testing of a Pediatric Chronic Graft- Versus-Host Disease (GVHD) Symptom Scale (PCSS)

Status: Recruiting
Location: See all (13) locations...
Study Type: Observational
SUMMARY

Background: Some children/adolescents who have had a stem cell transplant live with chronic graft-versus-host-disease (cGVHD). cGVHD is a side effect of the transplant that can cause multiple bothersome symptoms and negatively affect a child/adolescent squality of daily life. The questionnaires that measure thesymptoms caused by cGVHD are designed for adults. Children/adolescents may not describe their symptoms in the same way. The goal of this research is to improve the way we measure how bothersome these symptoms are for children/adolescents living with cGVHD.

Objective: To develop a questionnaire (The Pediatric cGHVD Symptom Scale) for children/adolescents living with cGVHD to identify the symptoms they are experiencing and describe how bothersome those symptoms are to them. An additional goal is to design a parent/guardian companion questionnaire that can be used to capture the symptom experiences of very young children who may not be able to complete a questionnaire.

Eligibility: Children/adolescents ages 5-17 who are receiving treatment for cGVHD after a stem cell transplant, and their parent/guardian..

Design: This study consists of 2 projects. Children/adolescents with cGVHD and their parent/guardianparticipants will be grouped by the child/adolescent s age: 5-7, 8-12, and 13-17. In project 1, participants will complete an age-appropriate questionnaire about cGVHD symptoms. The questionnaire will ask about the child/adolescent s physical functioning and emotional well-being. The parent/guardian will out fill out a companion questionnaire online. The child/adolescent will then review their completed questionnaire during an interview with a researcher and will be asked whether the questions about their symptoms were difficult to understand. The parent/guardian and child/adolescent will then be interviewed together to further explore their responses to the questionnaires. Interviews will be done in person, by phone, and online. . Based on what is learned through these interviews, the wording of the questionnaire will be improved for better comprehension and ease of response. In project 2, participants will complete this revised questionnairefor their age group along with some other questionnaires that ask about quality of life. Both the child/adolescent and parent/guardian will fill out the questionnaires online at three separate time points. In both projects, children/adolescents with cGVHD and their parent/guardian participants will be grouped by the child/adolescent s age: 5-7, 8-12, and 13-17. ...

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Healthy Volunteers: t
View:

⁃ Pediatric Participant Inclusion Criteria:

• Children aged 5 to 17 years old (Project 1) or children aged 8 to 17 years old (Project 2)

• Clinical diagnosis of cGVHD following allogeneic stem cell transplant

• Currently receiving systemic treatment for GVHD (including phototherapies), or has had systemic therapy for GVHD tapered to discontinuation within the past 12 months

• No evidence of malignant disease relapse including molecular relapse and minimal residual disease. Patients with mixed chimerism are eligible to participate

• Must have an eligible caregiver proxy who is willing to participate in the study.

• Parent or guardian ability and willingness to sign a written informed consent document

• Must be able to comprehend and speak the English language

• Participants may enroll in both Project 1 and Project 2 of the study. Participation in Project 1 is not required in order to be eligible to participate in Project 2.

⁃ Caregiver Proxy Inclusion Criteria

• Adult (\>=18 years old) caregiver of a child participating in Project 1 or Project 2; OR Adult (\>=18 years old) caregiver of a child aged 5 to 7 years old who meets all Pediatric Participant Inclusion Criteria except Project 2 criteria noted above in the section Pediatric Participant Inclusion Criteria

• Must be willing and able to provide informed consent

• Must be able to comprehend and speak the English language

⁃ EXCLUSOIN CRITERIA:

⁃ Children may be excluded from this study if in the judgment of the Principal or Associate Investigator, the child is too ill, or the child s cognitive ability would compromise their ability to participate in study related procedures.

Locations
United States
Colorado
Children's Hospital Colorado (CHCO)
RECRUITING
Aurora
Washington, D.c.
Children s National Medical Center (CNMC)
RECRUITING
Washington D.c.
Georgia
Children's Healthcare of Atlanta - Egleston Hospital
RECRUITING
Atlanta
Illinois
Lurie Children's Hospital of Chicago
RECRUITING
Chicago
Maryland
Johns Hopkins Hospital (JHH)
RECRUITING
Baltimore
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Minnesota
University of Minnesota
RECRUITING
Minneapolis
Pennsylvania
University of Pittsburgh - Children's Hospital of Pittsburgh
RECRUITING
Pittsburgh
Tennessee
St. Jude Children s Research Hospital
RECRUITING
Memphis
Texas
Texas Children's Hospital (TCH)-Baylor
RECRUITING
Houston
The University of Texas MD Anderson Cancer Institute
RECRUITING
Houston
Washington
Fred Hutchinson Cancer Center (FHCC)
RECRUITING
Seattle
Other Locations
Canada
Children's & Women's Health Centre of British Columbia (CWHC of BC)
RECRUITING
Vancouver Bc
Contact Information
Primary
Lori S Wiener, Ph.D.
lori.wiener@nih.gov
(240) 760-6419
Time Frame
Start Date: 2019-10-02
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 420
Treatments
1/Project 1 Child/caregiver-proxy
Children age 5-7 with cGVHD and their caregiver, n=20 child/parent dyads
2/Project 1 Child/caregiver-proxy
Children age 8-12 with cGVHD and their caregiver, n=35 child/parent pairs
3/Project 1 Child/caregiver-proxy
Children age 13-17 with cGVHD and their caregiver, n=35 child/parent pairs
4/Project 2 Child/caregiver-proxy
Children age 5-7 with cGVHD and their caregiver, n=40 child/parent pairs
5/Project 2 Child/caregiver-proxy
Children age 8-12 with cGVHD and their caregiver, n=40 child/parent pairs
6/Project 2 Child/caregiver-proxy
Children age 13-17 with cGVHD and their caregiver, n=40 child/parent pairs
Authors
Lori Wiener
Related Therapeutic Areas
Sponsors
Leads: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov